Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Non Operating Income (2016 - 2025)

Editas Medicine (EDIT) has disclosed Non Operating Income for 11 consecutive years, with -$568000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 11260.0% to -$568000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.2 million, a 151.06% decrease, with the full-year FY2024 number at -$3000.0, up 99.81% from a year prior.
  • Non Operating Income was -$568000.0 for Q3 2025 at Editas Medicine, up from -$1.7 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $4.3 million in Q2 2024 to a low of -$1.7 million in Q2 2025.
  • A 5-year average of $341333.3 and a median of -$2000.0 in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: skyrocketed 9342.11% in 2022, then tumbled 11260.0% in 2025.
  • Editas Medicine's Non Operating Income stood at -$1000.0 in 2021, then tumbled by 300.0% to -$4000.0 in 2022, then crashed by 250.0% to -$14000.0 in 2023, then soared by 78.57% to -$3000.0 in 2024, then tumbled by 18833.33% to -$568000.0 in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Non Operating Income are -$568000.0 (Q3 2025), -$1.7 million (Q2 2025), and $75000.0 (Q1 2025).